bendamustine actavis 2,5 mg/ml powder for concetrate for solution fo infusion
actavis group ptc ehf - bendamustin - 2,5 mg/ml powder for concetrate for solution fo infusion
bendamustine accord 2,5 mg/ml powder for concetrate for solution for infusion
2,5 mg/ml powder for concetrate for solution for infusion
bendamustine helm 2,5 mg/ml powder powder for concetrate for solution for infusion
2,5 mg/ml powder powder for concetrate for solution for infusion
bendamustine mylan 2,5 mg/ml powder for concentrate for solution for infusion
2,5 mg/ml powder for concentrate for solution for infusion
bendamustine sandoz 2,5 mg/ ml powder for concetrate for solution for infusion
2,5 mg/ ml powder for concetrate for solution for infusion
bendamustine alkaloid-int 2,5 mg/ml powder for concentate for solution for infusion
2,5 mg/ml powder for concentate for solution for infusion
bendamustine accord 25 mg/ml concetrate for solution for infusion
25 mg/ml concetrate for solution for infusion
rohomustin 2,5 mg/ml powder for concentrate for solution for infusion
sandoz d.d. - bendamustin - 2,5 mg/ml powder for concentrate for solution for infusion
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
betahistine aurobindo 8 mg tablets
aurobindo pharma (malta) limited - Бетагистина - 8 mg tablets